We found a match
Your institution may have access to this item. Find your institution then sign in to continue.
- Title
Mapping combinatorial drug effects to DNA damage response kinase inhibitors.
- Authors
Zhang, Hanrui; Kreis, Julian; Schelhorn, Sven-Eric; Dahmen, Heike; Grombacher, Thomas; Zühlsdorf, Michael; Zenke, Frank T.; Guan, Yuanfang
- Abstract
One fundamental principle that underlies various cancer treatments, such as traditional chemotherapy and radiotherapy, involves the induction of catastrophic DNA damage, leading to the apoptosis of cancer cells. In our study, we conduct a comprehensive dose-response combination screening focused on inhibitors that target key kinases involved in the DNA damage response (DDR): ATR, ATM, and DNA-PK. This screening involves 87 anti-cancer agents, including six DDR inhibitors, and encompasses 62 different cell lines spanning 12 types of tumors, resulting in a total of 17,912 combination treatment experiments. Within these combinations, we analyze the most effective and synergistic drug pairs across all tested cell lines, considering the variations among cancers originating from different tissues. Our analysis reveals inhibitors of five DDR-related pathways (DNA topoisomerase, PLK1 kinase, p53-inducible ribonucleotide reductase, PARP, and cell cycle checkpoint proteins) that exhibit strong combinatorial efficacy and synergy when used alongside ATM/ATR/DNA-PK inhibitors. DNA damage is a key component of many cancer therapies. Here, the authors utilised a dose-response combination screen of ATR, ATM and DNA-PK inhibitors, and identified combination treatments that achieves high combinatorial efficacy and synergy.
- Subjects
GERMANY (East); DNA repair; DNA topoisomerase I; PHARMACODYNAMICS; KINASE inhibitors; RIBONUCLEOSIDE diphosphate reductase; DNA damage
- Publication
Nature Communications, 2023, Vol 14, Issue 1, p1
- ISSN
2041-1723
- Publication type
Article
- DOI
10.1038/s41467-023-44108-y